U.S. health reviewers are concerned that clinicians may not be able to properly interpret brain scans using Eli Lilly & Co.’s imaging agent for Alzheimer’s and that the tests may be of limited use in assessing the degenerative disease.
The radioactive dye is intended for use with positron emission tomography, or PET, scans that help detect the presence of beta-amyloid plaques linked to Alzheimer’s disease. Get the full story »
